Meridian to Offer illumigene® Tests to Premier Hospitals
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Meridian Bioscience Inc. have signed a new agreement with Premier, Inc. to offer the complete illumigene® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
The illumigene molecular system utilizes loop-mediated isothermal DNA amplification (LAMP) technology, an efficient system which allows Meridian to provide customers the illumipro–10™ instrument without a capital investment or costly annual service contract. The illumigene procedure is simple, highly sensitive, and yields results in less than one hour, which helps drive improvements in the early diagnosis and treatment of preventable diseases.
Tags: Clostridium difficile, Mycoplasma, Bordetella pertussis, Group A Streptococcus, Group B Streptococcus
Date Published: September 15, 2014
Source article link: Meridian Bioscience, Inc. » company contact details
Group A Strep Detection in 18 Minutes With FDA and CLIA Waiver
Ultrasensitive C. diff Toxins A/B Assay Based on Single Molecule Counting Technology
Automating the Diagnosis of Urogenital Mycoplasma Infections
Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release
Rapid Mycoplasma Kit Qualified for Cell Therapy In-house QC